Related Experiment Video
Updated: May 7, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.0K
The Role of Genetic Testing in Localized Prostate Cancer.
Rebecca A Sager1, Gennady Bratslavsky2
1Department of Surgery - Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
The Urologic Clinics of North America
|November 20, 2025
Summary
Genetic testing is crucial for managing localized prostate cancer (PCa). Identifying germline variants aids in risk assessment and guides personalized screening and treatment strategies for PCa patients.
Area of Science:
- Oncology
- Genetics
- Genomics
Background:
- Genetic testing is vital for localized prostate cancer (PCa) management.
- Next-generation sequencing identifies germline and somatic alterations impacting PCa risk, prognosis, and treatment.
- 10-15% of PCa patients harbor pathogenic germline variants, notably in BRCA2, ATM, CHEK2, HOXB13, and mismatch repair genes.
Purpose of the Study:
- To highlight the growing importance of genetic testing in localized prostate cancer.
- To summarize current understanding of germline and somatic alterations in PCa.
- To outline the role of genetic information in guiding PCa management.
Main Methods:
- Review of current literature and guidelines on genetic testing in prostate cancer.
- Analysis of the prevalence and types of germline variants in PCa.
- Discussion of the application of genomic data in clinical decision-making.
Main Results:
- Germline variants are found in 10-15% of men with PCa.
- Key genes implicated include BRCA2, ATM, CHEK2, HOXB13, and mismatch repair genes.
- Routine germline testing is recommended for specific patient groups.
Conclusions:
- Genetic testing, including germline and somatic analyses, is integral to modern prostate cancer management.
- Genomic information assists in tailoring screening and treatment recommendations.
- Guidelines support germline testing for high-risk localized PCa and those with family history.
